COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 5 of 78 for:    somatostatin receptor | Neuroendocrine Tumors

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01237457
Recruitment Status : Unknown
Verified August 2015 by Ebrahim S. Delpassand, Excel Diagnostics and Nuclear Oncology Center.
Recruitment status was:  Active, not recruiting
First Posted : November 9, 2010
Last Update Posted : August 5, 2015
Radio Isotope Therapy of America
Information provided by (Responsible Party):
Ebrahim S. Delpassand, Excel Diagnostics and Nuclear Oncology Center

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : August 2015
Estimated Study Completion Date : October 2015